Alpha-1 Antitrypsin Dosing for aGVHD After HCT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute graft versus host disease (aGVHD) after hematopoietic cell transplantation (HCT) are limited in effectiveness and can negatively impact the HCT graft, with aGVHD being a leading cause of death and difficult to treat, particularly in allogeneic HCT patients.
Innovation Solution
Administering alpha-1 antitrypsin (A1AT) at specific dosages before and after the HCT procedure, including at least 120 mg/kg one day prior to HCT and 90 mg/kg twice weekly for at least 4 weeks post-HCT, optionally with immunosuppressive agents, to reduce the risk of aGVHD onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (steroids and immunosuppressants) are used to treat aGVHD, then aGVHD symptoms can be addressed, but the HCT graft is negatively affected and treatment success is limited
Solution Approach 1:
A1AT serves as an intermediary substance that mediates between the immune system and the HCT graft. It provides anti-inflammatory and immunomodulatory effects to treat aGVHD while avoiding direct T-cell suppression, thus protecting the graft from harmful immunosuppressive effects
Solution Approach 2:
The patent changes the therapeutic parameter from T-cell suppressing agents to A1AT administration at specific dosages (60-120 mg/kg). This parameter change achieves effective aGVHD treatment while maintaining graft integrity, as A1AT works through different mechanisms (protease inhibition, anti-inflammatory effects) rather than direct immunosuppression
2Reliability
If high dosage A1AT is administered to effectively treat aGVHD, then treatment efficacy improves, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent implements preliminary action by administering A1AT before HCT procedure (at least one day prior) to prevent aGVHD onset, and continues post-HCT treatment. This proactive approach simplifies overall management by preventing disease development rather than just treating symptoms after onset
Solution Approach 2:
The treatment follows a periodic action pattern with specific dosing schedules (at least twice weekly for 4 weeks, then once weekly for additional 4 weeks). This structured periodic administration maintains therapeutic efficacy while providing clear, manageable treatment protocols that reduce complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The A1AT regimen effectively reduces the risk of aGVHD, maintaining serum levels above normal for at least 28 days post-HCT, improving survival rates and minimizing graft impact.
Implementation Method 1
A1AT binds to enzymatic targets such as neutrophil elastase and has been shown to have anti-inflammatory, anti-neutrophil influx and activation, and anti-apoptotic effects on cells
Implementation Method 2
A1AT is not a T-cell suppressant and instead supports a tolerogenic hematopoietic profile
Data Source
AI summary
This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A 1A or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT.